OBJECTIVES: Interactions between antiretroviral treatment (ART) and comedications are a concern in HIV-infected patients. This study aimed to determine the frequency and severity of potential drug-drug interactions (PDDIs) with ART in our setting. 
Introduction
Recent advances in antiretroviral therapy (ART) have led to reductions in disease progression and improved survival in patients with human immunodeficiency virus (HIV) infection (1) . The increased life expectancy in this population has converted HIV into a chronic disease, and a large percentage of patients are older than 50 years (2) . This implies that increasingly more patients have comorbidities (both age-and HIV disease-related) and a greater need for various drug treatments (3) (4) (5).
In previous studies investigating the prevalence of potential drug-drug interactions (PDDIs) in several geographic regions, the rate of clinically relevant interactions between antiretrovirals and concomitant drugs is reported at 14% to 41% (6) (7) (8) (9) (10) (11) .
PDDIs can be associated with higher toxicity and lower effectiveness of both antiretrovirals and the comedications. Because of the inherent characteristics of antiretroviral drugs, many of which are enzyme inducers or inhibitors, PDDIs are common in HIV patients (12) .
Numerous articles, including some epidemiologic studies and reviews, have focused on pharmacokinetic interactions between different drugs (13) (14) (15) . Furthermore, excellent information sources contain recommendations for managing these interactions according to their severity. Nonetheless, epidemiologic studies on this subject and analyses of the clinical recommendations carried out are limited in large HIV cohorts (16) .
The primary aim of this study was to determine the prevalence and clinical relevance of the main PDDIs occurring in our setting, with a focus on the impact of a multidisciplinary team intervention used to manage this problem. Additional objectives were to analyze the most frequent antiretroviral drugs and comedications implicated in PDDIs, evaluate the risk factors for PDDIs, and determine the impact of these interactions on the effectiveness of ART.
Material and methods

Patients
Cross-sectional observational study including all HIV patients aged 18 years and older followed in Hospital del Mar (Barcelona, Spain) between March 2015 and March 2016.
Information on epidemiologic and sociodemographic factors, comorbidities, and the ART and comedications received was collected through a personal interview with each patient and by consulting the hospital Pharmacy Department's electronic database for antiretroviral drug dispensing and the electronic prescriptions in the patient's medical records. A structured questionnaire was used to compile information on all concomitant medications patients were taking: regular and occasional prescription drugs, over-the-counter drugs, recreational drugs, phytotherapy, and alternative medicine products. In addition, at the time of the structured interview, data were recorded on CD4 lymphocyte count, plasma viremia, and adherence to ART (determined by a specific questionnaire for this purpose and the Pharmacy drug-dispensing registry).
Identification and classification of drug-drug interactions
PDDIs between ART and comedications were evaluated using the University of Liverpool HIV Drug Interaction Checker (www.hiv-druginteractions.org) (17 
Results
Participants and characteristics of the medication
The study included 1259 patients from an overall cohort of approximately 1600 HIV-infected individuals. In total, 341 patients (23.1%) were excluded ( Figure 1 ). The characteristics of the participants are summarized in Table 1 . Most were Caucasian (81.2%) and men The characteristics of patients receiving comedications, presented according to whether or not a PPDI was detected are shown in Table 2 . As the table expresses numbers of patients, and an individual patient could be exposed to different antiretroviral classes, the antiretroviral groups are mutually exclusive in this order: PI, NNRTI, INI, MVC, and NRTI. The description of comedications by drug type, and the relationships between comedications and the presence and severity of PDDIs are described in Table 3 .
Prescription drugs, over-the-counter medications, and alternative medicine products are included. The most commonly prescribed therapies were cardiovascular and central nervous system (CNS) drugs, used in 53.8% and 40.2% of patients, respectively.
The recommendations proposed for patients with severe PDDIs and the concomitant drugs involved are summarized in Table 4 .
Factors associated with the presence of potential drug-drug interactions in patients receiving antiretroviral therapy and comedications
The univariate and multivariate analyses of factors associated with PDDI detection in patients on ART are described in Table 5 . After adjusting for demographic and HIV-related variables, the independent risk factors for the presence of PDDIs were hepatitis C virus (HCV) coinfection, ART regimen including a PI/r and/or NNRTI, and receiving ≥2 concomitant medications, with a significant increase in the risk of potential interactions when 4 or more concomitant drugs were used.
Recommendations for managing drug-drug interactions
The multidisciplinary team proposed 133 recommendations (23.6%; 133/563) for comedicated patients with PDDIs, and 91.7% (122/133) of the changes were accepted and carried out. The recommendations included a switch or dose adjustment of the concomitant treatment, or a switch or change in the timing of ART administration (Figure 1 ). Ninety-two (17.6%) changes were made for moderate PDDIs (n=522) and 30 changes (73.1%) for severe PDDIs (n=41). Recommendations for patients with severe PDDIs are described in 
Discussion
Drug-drug interactions in patients receiving ART can affect the toxicity, drug resistance, and therapeutic levels of the treatment (18); hence, it is essential to identify potential interactions to achieve effective viral suppression and minimal toxicity. The overall PDDI detection rate in our large cohort of HIV-infected patients was 44.7%, with 3.2% corresponding to potentially severe interactions and the remainder to moderate interactions. The factors predictive of presenting a PDDI were related to the number of comedications used, HCV coinfection, and the ART regimen.
Coadministration of ART with other medications can result in significant changes in serum levels of the drugs, many of which are associated with preventable adverse effects (19) .
Most drug-drug interactions take place through an inducing or inhibitory effect on the CYP450 cytochrome system and/or P-glycoprotein, and some antiretroviral drug classes are associated with a higher risk of developing interactions. Ritonavir-boosted PIs are potent Our results showed no difference in the adherence to ART or effectiveness of this treatment between patients with and without PDDIs, and there were no severe adverse events. One study has suggested that low rates of severe interactions result from medical care provided by expert specialists in HIV (16) . In approximately one-quarter of our patients receiving concomitant medication, potential interactions were detected and a recommendation was needed beyond the usual clinical practice.
The limitations of this study, in addition to the variability in the classification of PDDIs, is that, as a single center study the findings are difficult to extrapolate to other health care settings, because of the type of patient included, the health professionals involved, and the antiretroviral drugs used. These factors can modify not only the percentage and severity of PDDIs, but also the need for monitoring and counseling.
The findings of the present study indicate that recording and assessing the medications (antiretrovirals and others) taken by HIV-infected patients is effectively achieved through the work of a multidisciplinary team (physicians experienced in HIV and specialized clinical pharmacists) to anticipate drug-drug interactions, improve the quality of the prescriptions, and guarantee patient safety.
Conflicts of interests
The authors declare that they have no conflicts of interest related to this article. ARV, antiretroviral; PI/r, ritonavir-boosted protease inhibitor; ATZ/r, atazanavir/ritonavir; SQV/r, saquinavir/ritonavir; RPV, rilpivirine; NVP, nevirapine; NNRTIs, non-nucleoside reverse transcriptase inhibitors 
